Best Life Sciences Platforms and Tools Companies in North Rhine Westphalia, Germany
The 62 best Life Sciences Platforms and Tools companies in North Rhine Westphalia, Germany in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Singleron.
Our analysis of 50 Life Sciences Platforms and Tools companies
$4.8b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Platforms and Tools companies in North Rhine Westphalia
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Singleron Developer of single-cell multi-omics platform for clinical research and molecular diagnosis | $84M | 55 mo ago | — | 2018 | Jing Zhou Co-Founder | WordPressMySQLPHP+16 | — | — |
| 2 | Cevec Pharmaceuticals Provider of glyco-optimised human cell lines and gene therapy vectors using proprietary cell expression system | $28M | 59 mo ago | 39 | 2001 | — | — | 208 patents Production and engineering of viral vectors and glyco-modified recombinant therapeutics. | — |
| 3 | Ayoxxa Biosystems Developer of a platform for multiplex protein analysis | $19M | 113 mo ago | 40 | 2010 | — | — | 4 patents Patents concentrated in computing, sensing & instrumentation | — |
| 4 | PL BioScience Manufacturer of human platelet lysate products for cell culture applications | $13M | 22 mo ago | 13 | 2015 | Hatim Hemeda CEO | Cart FunctionalityWooCommerceWordPress+42 | 15 patents Patents concentrated in chemistry & materials | 2 launchs · 1 partnership · 1 award |
| 5 | LenioBio Provider of kit for cell-free protein expression for accelerating drug delivery 50Talent top 28%Funding top 37%Moat top 37%Tech top 39% All 10 signals ▾Talenttop 28% Fundingtop 37% Moattop 37% Techtop 39% Patentstop 41% Growthtop 45% Innovationtop 47% Globalbottom 39% Marketbottom 33% Newsbottom 22% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $13.0M across 6 rounds · 6 rounds over 7 yrs (0.9/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $13M | 11 mo ago | 18 18 → 44 (+144%) | 2016 | Remberto Martis Founder & CEO | WordPress Block EditorElementorWordPress+30 | 20 patents Cell-free protein synthesis platforms and high-throughput transmembrane ligand screening technologies. | — |
| 6 | Miltenyi Biotec Develops tools and products for research and clinical application | $13M | 63 mo ago | 585 | 1989 | Stefan Miltenyi Founder & MD | Cart FunctionalityApple iCloud MailMicrosoft 365+19 | 875 patents Advanced cell therapy manufacturing, immune cell engineering, and microfluidic sorting platforms | — |
| 7 | Neuway Pharma Therapies for the treatment of brain diseases using its proprietary CNS drug delivery platform | $7M | 120 mo ago | 18 | 2014 | — | — | 33 patents Virus-like particle platforms for mRNA and protein therapeutic delivery | — |
| 8 | Nexigen Developer of therapies for oncological indications | $6M | 180 mo ago | 10 | 2007 | — | — | 24 patents Protein‑peptide interaction detection platforms for antiviral target discovery and therapeutics | — |
| 9 | SenseUP Developer of microbial production strains 21Talent top 35%Moat top 38%Patents top 49%Funding bottom 45% All 7 signals ▾Talenttop 35% Moattop 38% Patentstop 49% Fundingbottom 45% Globalbottom 40% Innovationbottom 37% Marketbottom 23% Talent: 4 named leaders on record Moat: Editorial + unicorn rating 5/10 · IP moat: 14 patents rank vs industry peers · Fliar Intelligence Index 21/100 | $3M | 13 mo ago | 10 10 → 13 (+30%) | 2015 | Gunter Festel Co-Founder | — | 14 patents RNA synthesis platforms and aptamer-based biosensors for microbial protein detection | — |
| 10 | Cellex Developer of stem cells for cancer treatment | $2M | 195 mo ago | 127 | 2001 | Carla Kreissig Co-CEO | Apple iCloud MailNode.jsVue.js+8 | — | — |
| 11 | Chimera Biotec Company offering bioanalytical services and immunoassay platforms for ultra sensitive large-molecule… | $1M | 117 mo ago | 11 | 2001 | Mark Spengler CEO | TYPO3 CMSPHPLeaflet+9 | 20 patents Quantitative detection of biomolecules using conjugated assay reagents and optical devices. | — |
| 12 | LaVision BioTec Developer of microscopes for cell analysis and preclinical imaging | $1M | 53 mo ago | 102 | 2000 | — | — | 40 patents Advanced optical microscopy: light-sheet and single-molecule localization imaging systems | — |
| 13 | Bitop Develops reagents for bioactive compound, cosmetic active ingredient, and biostabilizer | $608K | 101 mo ago | 41 | 1993 | Daniel Berger CEO | StatamicApple iCloud MailMicrosoft 365+14 | 201 patents Pharmaceutical formulations for ocular treatments, sirtuin activation, and antiviral solutes. | — |
| 14 | Evoxx Technologies Developer of enzymes and bio-catalytic processes | $554K | 137 mo ago | 15 | 2006 | — | — | — | — |
| 15 | SeSaM-Biotech Technologies and solutions for protein engineering | $542K | 113 mo ago | 5 | 2008 | Ulrich Schwaneberg Founder | — | — | — |
| 16 | Fibrothelium Developer of silk protein derived from silkworm cocoons | $302K | 69 mo ago | — | 2017 | Hans Leemhuis Chief Executive Officer | — | 13 patents Silk fibroin biomaterials for medical implants, drug delivery, and therapeutic protein production | — |
| 17 | Axel Semrau Developer of system solutions and analytical instruments for laboratories | $251K | 75 mo ago | 50 50 → 27 (-46%) | 1981 | Andreas Bruchmann Managing Director | TYPO3 CMSPHPBootstrap+14 | — | — |
| 18 | NUMAFERM Developer of recombinant antimicrobial and adhesive peptides | $114K | 87 mo ago | 11 11 → 18 (+64%) | 2017 | Philipp Buerling Co-Founder | Cart FunctionalityWordPressMySQL+13 | 38 patents Protein engineering tools: fusion tags, C‑terminal peptide modification, and TEV protease variants. | 1 job opening |
Top 12 Life Sciences Platforms and Tools companies in North Rhine Westphalia
#1
Series A · Dusseldorf, North Rhine Westphalia · founded 2016 · 18 employees$13Mraised▾
Provider of kit for cell-free protein expression for accelerating drug delivery. The company develops ALiCE is the first eukaryotic cell-free protein expression platform for the discovery, development, and production of difficult-to-express proteins. It has active energy regeneration and has components necessary for protein folding, disulfide bonding, and glycosylation.
- Jul 2025Grant (prize money)$4.3M
- Sep 2023Grant (prize money)—
- May 2022Grant (prize money)$2.9M
- Feb 2022Grant (prize money)$56.3K
#2
Seed · Julich, North Rhine Westphalia · founded 2015 · 10 employees$2.7Mraised▾
SenseUp is a developer of microbial production strains. The company uses patented meta sensor technology to screen strains of bacteria, with higher productivity. The technology has applications for train development, SNP identification, library screening, and process dynamics analysis. It also offers a product like amino acids, proteins and peptides, RNA and other natural products.
- May 2025Seed$2.7M
#3
Series A · Aachen, North Rhine Westphalia · founded 2015 · 13 employees$13Mraised▾
Manufacturer of human platelet lysate products for cell culture applications. The company offers a range of platelet lysate products with different safety grades. These products support cell expansion for research, therapeutics, and clinical applications. The company's technology aims to provide solutions for cell culture needs.
- Aug 2024Series A$8.5M
- May 2021Series A$4.5M
#4
Series B · Hagen, North Rhine Westphalia · founded 2018$84.5Mraised▾
Developer of single-cell multi-omics platform for clinical research and molecular diagnosis. It offers a product portfolio that includes instruments, microfluidic devices, reagents, software analysis, and database solutions that facilitate high-throughput single-cell analysis. It also, offers single cell sequencing services.
- Nov 2021Series B—
- Dec 2020Series A$30M
- Nov 2020Series A$10M
- Sep 2020Series A$30M
#5
Acquired · Cologne, North Rhine Westphalia · founded 2001 · 39 employees$28.4Mraised▾
Provider of glyco-optimized human cell lines and gene therapy vectors using proprietary cell expression system. The company has ELEVECTA technology for AAV manufacturing, CAP Go expression platform comprises a portfolio of glyco-optimized human suspension cell lines for tailor-made glycosylation of recombinant proteins. Provides the CAP GT expression platform, a scalable production system for gene therapy vectors. Also offers cell line development and protein expression services.
- Jul 2021Series E—
- Apr 2019Series D—
- Jul 2015Series C$4.9M
- Oct 2012Series C$3.6M
#6
Funding Raised · Bergisch Gladbach, North Rhine Westphalia · founded 1989 · 585 employees$12.7Mraised▾
Develops tools and products for research and clinical application. The company offers biomedical research and cellular therapy products for cell isolation, flow cytometry, sample preparation, cell culture, molecular analysis, clinical application, and imaging. They have expertise in immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis.
- Mar 2021Grant (prize money)$304.4K
- Jan 2021Grant (prize money)$821.7K
- Jan 2020Grant (prize money)$539.1K
- Jun 2019Grant (prize money)$283.1K
#7
Deadpooled · Cologne, North Rhine Westphalia · founded 2010 · 40 employees$18.5Mraised▾
Ayoxxa Biosystems developed a technology platform for multiplexed protein analysis. The company's proprietary platform includes Lunaris BioChip that is used to identify and quantify proteins, including markers for cancer, allergies, cardiovascular or infectious diseases. It can be useful in biomedical research, pharmacological screening, and preclinical diagnostics development. The company also offers disease-specific detection kits such as 6-Plex Cytokine Kits to analyze biomarkers that are important in inflammation and in immune regulation.
- Jan 2017Grant (prize money)$21.9K
- May 2015Grant (prize money)$681.5K
- Dec 2014Series B$2.9M
- Jun 2014Series B$12.3M
#8
Public · Bonn, North Rhine Westphalia · founded 2014 · 18 employees$7.2Mraised▾
Neuway Pharma, a spin-off from Life Science Inkubator is focussed on the preclinical and clinical development of therapies for the treatment of orphan brain diseases based on its proprietary CNS drug delivery platform. With its technology platform, it is developing an alternative transportation system to the CNS which has the potential to protect the human brain from toxins and inhibits the penetration of drug molecules into the brain. Its engineered protein capsules (EPCs) can be loaded with a large variety of therapeutic active substances. The company is also planning to partner its drug delivery technology for other CNS indications.
- Jun 2016Grant (prize money)$3.3M
- Oct 2015Series A$3.6M
- May 2014Series A$3.7M
#9
Acquired · Bielefeld, North Rhine Westphalia · founded 2000 · 102 employees$1.3Mraised▾
LaVision BioTec develops microscopes for cell analysis and preclinical imaging. The products of the company include light sheet microscope for fluorescence imaging, horizontal photon laser scanning microscope, modular 2-photon microscope platform, the doubleheader microscope, endomicroscope, etc. The products have their applications on various therapeutic segments such as neuroscience, immunology, oncology, and developmental biology.
- Jan 2022Grant (prize money)$901.3K
- Jan 2021Grant (prize money)$383.4K
#10
Deadpooled · Cologne, North Rhine Westphalia · founded 2007 · 10 employees$5.9Mraised▾
Nexigen is developing drugs with a focus on oncological indications. They have developed a proprietary screening technology, NexiScreen, which identifies disease relevant protein-protein interactions and detects target interacting peptides. Their lead candidate, NexC1004, which acts through the hedgehog signaling pathway. The candidate is being investigated for various malignancies.
- Jun 2011Series A$5.9M
#11
Funding Raised · Dortmund, North Rhine Westphalia · founded 2001 · 11 employees$1.4Mraised▾
Chimera Biotec has developed a proprietary immunoassay platform called Imperacer for ultra-sensitive large molecule bioanalysis. The company claims to be the world's leading Immuno-PCR (IPCR) based technology vendor. The company's products include the Imperacer Workstation, Assay Development Kits and maintenance kit. Services offered include assay development, method validation, and bioanalysis.
- Sep 2016Grant (prize money)$225K
- Mar 2016Grant (prize money)$75K
- May 2015Grant (prize money)$918.9K
- Apr 2015Grant (prize money)$226.3K
#12
Funding Raised · Cologne, North Rhine Westphalia · founded 2001 · 127 employees$2Mraised▾
Cellex is developing stem cells for cancer treatment in collaboration with GEMoaB Monoclonals. They have developed their universal CAR technology (UniCAR) where immune cells are taken and modified with a surface protein known as chimeric antigen receptor (CAR-T).
- Mar 2010Grant (prize money)$2M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Platforms and Tools coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics is moving in Germany
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 2,605 Germany-affiliated papers.
- Heidelberg University245
- German Cancer Research Center123
- Charité - Universitätsmedizin Berlin95
- Goethe University Frankfurt94
- Ludwig-Maximilians-Universität München91
- Genome13→106
- Gene16→108
- Transcriptome6→61
- Epigenetics2→40
- Context (archaeology)1→33
- Disease1→62
- Gene3→49
- Immune system1→41
- Transcriptome4→37
- Biomarker1→29
- Disease2→41
- Immune system1→29
- Gene4→24
- Genome2→20
- Cancer1→14
Where bioinformatics is researched across Germany
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.